Skip to main content

Advertisement

SpringerLink
Log in

Effect of Antiviral Prophylaxis Strategy for Chemotherapy-Associated Hepatitis B Reactivation in Non-Hodgkin’s Lymphoma Patients with Hepatitis B Virus Infection: A Retrospective Cohort Study

  • Original Article
  • Published:
Indian Journal of Hematology and Blood Transfusion Aims and scope Submit manuscript

Abstract

Recent data indicates that nucleoside/nucleotide analogue (NUC) is effective in preventing and controlling hepatitis B virus (HBV) reactivation in HBV-carrying cancer patients who undergo chemotherapy, but the ideal antiviral agent and optimal application protocol still needs to be determined. Meanwhile, it is uncertain whether those with past HBV infection require antiviral prophylaxis during chemotherapy. This report retrospectively analyzed non-Hodgkin’s lymphoma (NHL) patients seen from January, 2004 to June, 2009 in West China Hospital. We found that the prevalence of chronic HBV infection in our NHL patients was 20.7 % while that of past HBV infection was 21.05 %. Compared with the high rate (25.6 %) of HBV reactivation in patients with chronic HBV infection, none of those with past HBV infection in fact had occult HBV infection thus none experienced reactivation. Of the 82 patients with chronic HBV infection who received chemotherapy, antiviral prophylaxis could significantly reduce the incidence of HBV reactivation (5.0 vs. 45.2 % in the control group) and the incidence of liver function damage (32.5 vs. 73.8 % in the control group). The results of the current study confirmed previous reports that prophylactic NUCs administration can effectively prevent HBV reactivation and significantly reduce the incidence of HBV reactivation especially for patients receiving rituximab-containing regimens. Due to the fact that none of individuals who had past HBV infection developed HBV reactivation reported in our study, antiviral prophylaxis may not be required for patients with past HBV infection. Close observation of alanine aminotransferase and HBV–DNA contributes to early diagnosis and timely treatment of HBV reactivation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Liang XF, Chen YS, Wang XJ, He X, Chen LJ, Wang J, Lin CY, Bai HQ, Yan J, Cui G, Yu JJ (2005) A study on the sero-epidemiology of hepatitis B in Chinese population aged over 3-years old. Zhonghua Liu Xing Bing Xue Za Zhi 26(9):655–658

    PubMed  Google Scholar 

  2. Schmeltzer P, Sherman KE (2010) Occult hepatitis B: clinical implications and treatment decisions. Dig Dis Sci 55(12):3328–3335. doi:10.1007/s10620-010-1413-0

    Article  PubMed Central  PubMed  Google Scholar 

  3. Qin XT, Lu Y, Chen XQ, Xu HP, Fan HJ (2007) Correlation of hepatitis B virus infection to non-Hodgkin’s lymphoma. Ai Zheng 26(3):294–297. doi:http://www.ncbi.nlm.nih.gov/pubmed/17355794

    CAS  PubMed  Google Scholar 

  4. Li YH, He YF, Jiang WQ, Wang FH, Lin XB, Zhang L, Xia ZJ, Sun XF, Huang HQ, Lin TY, He YJ, Guan ZZ (2006) Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 106(6):1320–1325. doi:10.1002/cncr.21701

    Article  CAS  PubMed  Google Scholar 

  5. Liao CA, Lee CM, Wu HC, Wang MC, Lu SN, Eng HL (2002) Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin’s lymphoma. Br J Haematol 116(1):166–169

    Article  CAS  PubMed  Google Scholar 

  6. Rossi G (2003) Prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with hemato-oncological neoplasias treated with chemotherapy. Leuk Lymphoma 44(5):759–766. doi:10.1080/104281903100006351

    Article  CAS  PubMed  Google Scholar 

  7. Rossi G, Pelizzari A, Motta M, Puoti M (2001) Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 115(1):58–62

    Article  CAS  PubMed  Google Scholar 

  8. Yeo W, Chan PK, Ho WM, Zee B, Lam KC, Lei KI, Chan AT, Mok TS, Lee JJ, Leung TW, Zhong S, Johnson PJ (2004) Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 22(5):927–934. doi:10.1200/JCO.2004.05.161

    Article  CAS  PubMed  Google Scholar 

  9. Sera T, Hiasa Y, Michitaka K, Konishi I, Matsuura K, Tokumoto Y, Matsuura B, Kajiwara T, Masumoto T, Horiike N, Onji M (2006) Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med 45(11):721–724

    Article  PubMed  Google Scholar 

  10. Dervite I, Hober D, Morel P (2001) Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 344(1):68–69. doi:10.1056/NEJM200101043440120

    Article  CAS  PubMed  Google Scholar 

  11. Domingo-Domenech E, Gonzalez-Barca E, Estany C, Sureda A, Besalduch J, Fernandez de Sevilla A (2002) Combined treatment with anti-CD20 (rituximab) and CHOP in relapsed advanced-stage follicular lymphomas. Haematologica 87(11):1229–1230

    CAS  PubMed  Google Scholar 

  12. Law JK, Ho JK, Hoskins PJ, Erb SR, Steinbrecher UP, Yoshida EM (2005) Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 46(7):1085–1089. doi:10.1080/10428190500062932

    Article  PubMed  Google Scholar 

  13. Sarrecchia C, Cappelli A, Aiello P (2005) HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother 11(4):189–191. doi:10.1007/s10156-005-0385-z

    Article  PubMed  Google Scholar 

  14. Targhetta C, Cabras MG, Mamusa AM, Mascia G, Angelucci E (2008) Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy. Haematologica 93(6):951–952. doi:10.3324/haematol.12557

    Article  PubMed  Google Scholar 

  15. Koo YX, Tan DS, Tan IB, Tao M, Chow WC, Lim ST (2010) Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy. Cancer 116(1):115–121. doi:10.1002/cncr.24742

    CAS  PubMed  Google Scholar 

  16. Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, Hui P, Leung NW, Zee B, Johnson PJ (2000) Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 62(3):299–307. doi:10.1002/1096-9071

    Article  CAS  PubMed  Google Scholar 

  17. Liang R, Lau GK, Kwong YL (1999) Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol 17(1):394–398

    CAS  PubMed  Google Scholar 

  18. Kohrt HE, Ouyang DL, Keeffe EB (2006) Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther 24(7):1003–1016. doi:10.1111/j.1365-2036.2006.03081.x

    Article  CAS  PubMed  Google Scholar 

  19. Yeo W, Johnson PJ (2006) Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 43(2):209–220. doi:10.1002/hep.21051

    Article  CAS  PubMed  Google Scholar 

  20. Dai MS, Wu PF, Lu JJ, Shyu RY, Chao TY (2004) Preemptive use of lamivudine in breast cancer patients carrying hepatitis B virus undergoing cytotoxic chemotherapy: a longitudinal study. Support Care Cancer 12(3):191–196. doi:10.1007/s00520-003-0549-2

    Article  PubMed  Google Scholar 

  21. Shibolet O, Ilan Y, Gillis S, Hubert A, Shouval D, Safadi R (2002) Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 100(2):391–396

    Article  CAS  PubMed  Google Scholar 

  22. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS (2007) Management of hepatitis B: summary of a clinical research workshop. Hepatology 45(4):1056–1075. doi:10.1002/hep.21627

    Article  CAS  PubMed  Google Scholar 

  23. European Association for the Study of the Liver (2009) EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 50(2):227–242. doi:10.1016/j.jhep.2008.10.001

    Article  Google Scholar 

  24. European Association for the Study of the Liver (2012) EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 57(1):167–185. doi:10.1016/j.jhep.2012.02.010

    Google Scholar 

  25. Fukushima N, Mizuta T, Tanaka M, Yokoo M, Ide M, Hisatomi T, Kuwahara N, Tomimasu R, Tsuneyoshi N, Funai N, Sueoka E (2009) Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol 20(12):2013–2017. doi:10.1093/annonc/mdp230

    Article  CAS  PubMed  Google Scholar 

  26. Tsutsumi Y, Shigematsu A, Hashino S, Tanaka J, Chiba K, Masauzi N, Kobayashi H, Kurosawa M, Iwasaki H, Morioka M, Asaka M, Imamura M (2009) Analysis of reactivation of hepatitis B virus in the treatment of B cell non-Hodgkin’s lymphoma in Hokkaido. Ann Hematol 88(4):375–377. doi:10.1007/s00277-008-0585-6

    Article  PubMed  Google Scholar 

  27. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, Hui EP, Lei KI, Mok TS, Chan PK (2009) Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 27(4):605–611. doi:10.1200/JCO.2008.18.0182

    Article  CAS  PubMed  Google Scholar 

  28. Dai MS, Chao TY, Kao WY, Shyu RY, Liu TM (2004) Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol 83(12):769–774. doi:10.1007/s00277-004-0899-y

    Article  CAS  PubMed  Google Scholar 

  29. Tsutsumi Y, Kanamori H, Mori A, Tanaka J, Asaka M, Imamura M, Masauzi N (2005) Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf 4(3):599–608. doi:10.1517/14740338.4.3.599

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Dr. Jin Liu in the gathering of clinical data for this study and all Faculties of the Department of Hematology, West China Hospital of Sichuan University, for their kind assistance.

Author information

Authors and Affiliations

  1. West China School of Clinical Medicine, Sichuan University, No. 37 Guoxue Alley, Chengdu, China

    Fan Yang

  2. Department of Haematology, West China Hospital of Sichuan University, No. 37 Guoxue Alley, Chengdu, China

    Huan-Ling Zhu, Chuan He, Jian-Jun Li, Bing Xiang, Xu Cui, Jie Huang, Jie Ji, Hong-Bing Ma & Ting Liu

Authors
  1. Fan Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Huan-Ling Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chuan He
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jian-Jun Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bing Xiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xu Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jie Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jie Ji
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hong-Bing Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ting Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Huan-Ling Zhu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yang, F., Zhu, HL., He, C. et al. Effect of Antiviral Prophylaxis Strategy for Chemotherapy-Associated Hepatitis B Reactivation in Non-Hodgkin’s Lymphoma Patients with Hepatitis B Virus Infection: A Retrospective Cohort Study. Indian J Hematol Blood Transfus 30, 97–104 (2014). https://doi.org/10.1007/s12288-012-0195-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12288-012-0195-2

Keywords

Search

Navigation